Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Food Policy
Interventions: Policy; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3,488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dermatitis Atopic
Interventions: PF-07038124 and Vehicle, PF-07038124 or vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions: Methylprednisolone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 25 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Duarte, California • Glendora, California • Irvine, California + 4 more

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Esophageal Cancer
Interventions: Radiation, Paclitaxel, Cisplatin, 5-Fluorouracil; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Lorlatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: 90Y-DOTA-tyr3-OCTREOTIDE; Radiation
Lead sponsor: O'Dorisio, M S; Other
Eligibility: 2 Years to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Postoperative Pain
Interventions: Exparel plus plain bupivacaine, Bupivacaine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Compartment Syndrome of Leg, Healthy
Interventions: Mepivacaine Injection; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Athletic Injuries
Interventions: Diclofenac hydroxyethylpyrrolidine; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more

Conditions: Diabetes Mellitus
Interventions: Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anesthesia, Local, Intravitreal Injection, Macular Degeneration, Diabetic Macular Edema
Interventions: Cooling Anesthesia; Device
Lead sponsor: Recens Medical, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Reno, Nevada • Houston, Texas

Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Interventions: Zanzalintinib, Cetuximab, Pembrolizumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Degenerative Disc Disease, Spinal Fusion
Interventions: TGplPTH1-34 in fibrin, Autologous Bone Graft; Combination Product · Other
Lead sponsor: Kuros Biosurgery AG; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Boulder, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Thoracic Surgery
Interventions: Liposomal Bupivacaine (EXPAREL®)/Bupivacaine, Ropivacaine (0.5% bolus followed by 0.2% infusion); Drug
Lead sponsor: Poovendran Saththasivam; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: Osteoarthritis
Interventions: Ropivacaine infiltration and saline infusion., Ropivacaine infiltration and infusion., Normal Saline; Procedure
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Knee Arthropathy
Interventions: Placement of an adductor canal nerve block; Procedure
Lead sponsor: Drexel University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypospadias, Penile Torsion, Chordee, Phimosis
Interventions: Caudal Block, Ultrasound-guided Pudendal Block, Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine, Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.; Procedure · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Months to 3 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anesthesia, Local
Interventions: Not listed
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Wrist Injuries, Postoperative Pain Control
Interventions: 20ml bolus of 0.5% ropivicaine, 10 ml of 0.5% ropivicaine, Midazolam, Fentanyl; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Local Anesthetics
Interventions: Lidocaine, normal saline, alkalinized lidocaine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 19 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Houston, Texas

Conditions: Nasopharyngeal Carcinoma
Interventions: Toripalimab, Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Impact of the Minneapolis Staple Foods Ordinance

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Local Anesthetics on Postsurgical Analgesia Following Posterior Colporrhaphy

Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Cooling Anesthesia for Intravitreal Injection

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

Local Anesthetic as Single Shot Versus Catheter in Patients Undergoing Video Assisted Thoracoscopic Surgery

Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement

Defining the Optimal Location to Place an Adductor Canal Block

Caudal vs. Pudendal Block in Peds GU

Changes in Tissue Oxygenation Following Regional Anesthesia

Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery

Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)